Evelo Bio rais­es $47.5M for I/O work; Ver­tex gets start­ed on a fast piv­otal ef­fort for triple CF com­bo

→ Sev­en months af­ter Google-backed Evelo Bio­sciences brought its to­tal ven­ture raise to $100 mil­lion, the mi­cro­bial ex­perts are at it again. Evelo has raised an­oth­er $47.5 mil­lion, ac­cord­ing to a new fil­ing with the SEC. Flag­ship Pi­o­neer­ing seed­ed Evelo and has helped to keep a mar­quee group of in­vestors be­hind the com­pa­ny, which merged two fledg­ling op­er­a­tions in­to one. The big idea here is that Evelo be­lieves it has the tech need­ed to ad­vance a new im­muno-on­col­o­gy drug at a time the lead PD-1/L1 ther­a­pies are be­com­ing se­mi-com­modi­tized as a new wave of check­point ther­a­pies hits the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.